MedImmune's Mott starts new career in VC

John Carroll — Thu, 18 Sep 2008 11:43:02 -0400

MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he will focus on biotechnology and specialty pharma.

Mott left MedImmune last July, a year after it was bought out by AstraZeneca for $15.6 billion. And the acquisition didn't leave Mott hurting for money. He got $133.5 million in stock option payouts and $12.2 million in other money.

"His broad sector expertise and strong ties within the biopharma community add substantial depth to NEA's healthcare practice," Peter J. Barris, a managing general partner, said in a statement.

- see NEA's release
- read the story from the Washington Post

MedImmune’s Mott heads for the exit

John Carroll — Thu, 26 Jun 2008 11:35:02 -0400

David Mott, the CEO of MedImmune who led his company through a $15.6 billion buyout by AstraZeneca, is leaving the company a year after the deal closed. Mott says he's leaving for personal reasons and not because of any management disagreements. Following the AstraZeneca buyout, MedImmune was tapped to head the pharma giant's biologics work, integrating Cambridge Antibody Technology with the Maryland developer. Tony Zook, who heads AstraZeneca's North American operation, will take Mott's place until a successor is named.

The buyout didn't sit well with all the analysts several of whom said AstraZeneca paid too much. And one anonymous analyst told Thomson Financial that with Mott out of the picture AstraZeneca had lost a potentially strong successor to AstraZeneca CEO David Brennan.

- read the story from Thomson Financial